［1］Kind T,Tolstikov V,Fiehn O,et al.A comprehensive urinary metabolomic approach for identifying kidney cancer［J］.Analytical Biochem,2007,363(2):185-195.
［2］Wojakowska A,Chekan M,Widlak P,et al.Application of Metabolomics in Thyroid Cancer Research［J］.Int J Endocrinol,2015,2015:258763.
［3］Cheng L,Zhang S,MacLennan GT,et al.Laser-assisted microdissection in translational research:theory,technical considerations,and future applications［J］.Applied Immunohistochem Mol Morphol,2013,21(1):31-47.
［4］Li L,Han J,Wang Z,et al.Mass spectrometry methodology in lipid analysis［J］.Int J Mol Sci,2014,15(6):10492-10507.
［5］Benayad Z,Gómez-Cordovés C,Es-Safi NE.Characterization of flavonoid glycosides from fenugreek (Trigonella foenum-graecum) crude seeds by HPLC-DAD-ESI/MS analysis［J］.Int J Mol Sci,2014,15(11):20668-20685.
［6］Kouremenos KA,Johansson M,Marriott PJ.Advances in gas chromatographic methods for the identification of biomarkers in cancer［J］.J Cancer,2012,3:404.
［7］Mahrous EA,Farag MA.Two dimensional NMR spectroscopic approaches for exploring plant metabolome:A review［J］.J Advanced Res,2015,6(1):3-15.
［8］Miccoli P,Torregrossa L,Shintu L,et al.Metabolomics approach to thyroid nodules:A high-resolution magic-angle spinning nuclear magnetic resonance-based study［J］.Surgery,2012,152(6):1118-1124.
［9］Tripathi P,Somashekar BS,Ponnusamy M,et al.HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease［J］.J Proteome Res,2013,12(7):3519-3528.
［10］Glunde K,Bhujwalla ZM.Metabolic tumor imaging using magnetic resonance spectroscopy［J］.Seminars in Oncol,2011,38(1):26-41.
［11］Lietz CB,Gemperline E,Li L.Qualitative and quantitative mass spectrometry imaging of drugs and metabolites［J］.Advanced Drug Delivery Reviews,2013,65(8):1074-1085.
［12］Ellis SR,Brown SH,in het Panhuis M,et al.Surface analysis of lipids by mass spectrometry:more than just imaging［J］.Progress in Lipid Res,2013,52(4):329-353.
［13］Sun N,Walch A.Qualitative and quantitative mass spectrometry imaging of drugs and metabolites in tissue at therapeutic levels［J］.Histochem Cell Biol,2013,140(2):93-104.
［14］Ke CF,Zhang T,Wu XY,et al.Metabonomics statistical methods of data analysis［J］.Chin J Health,2014,31(2):357-359.［柯朝甫,张涛,武晓岩,等.代谢组学数据分析的统计学方法［J］.中国卫生统计,2014,31(2):357-359.］
［15］Goodacre R,Broadhurst D,Smilde AK,et al.Proposed minimum reporting standards for data analysis in metabolomics［J］.Metabolomics,2007,3(3):231-241.
［16］Kirwan JA,Weber RJM,Broadhurst DI,et al.Direct infusion mass spectrometry metabolomics dataset:a benchmark for data processing and quality control［J］.Scientific Data,2014,1:140012.
［17］Ellinger JJ,Chylla RA,Ulrich EL,et al.Databases and software for NMR-based metabolomics［J］.Current Metabolomics,2013,1(1):10.
［18］Wishart DS,Jewison T,Guo AC,et al.HMDB 3.0-The human metabolome database in 2013［J］.Nucleic Acids Res,2013,41:D801-D807.
［19］Schultz AW,Wang J,Zhu ZJ,et al.Liquid chromatography quadrupole time-of-flight characterization of metabolites guided by the METLIN database［J］.Nature Protocols,2013,8(3):451.
［20］Kopka J,Schauer N,Krueger S,et al.Metabolome database［J］.Bioinformatics,2005,21(8):1635-1638.
［21］Johnson SR,Lange BM.Open-access metabolomics databases for natural product research:present capabilities and future potential［J］.Frontiers in Bioengineering and Biotechnol,2015,3:22.
［22］Fahy E,Sud M,Cotter D,et al.LIPID MAPS online tools for lipid research［J］.Nucleic Acids Res,2007,35(suppl 2):W606-W612.
［23］Boss EA,Moolenaar SH,Massuger LFAG,et al.High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid［J］.NMR in Biomedicine,2000,13(5):297-305.
［24］Chen J,Zhou L,Zhang X,et al.Urinary hydrophilic and hydrophobic metabolic profiling based on liquid chromatography-mass spectrometry methods:Differential metabolite discovery specific to ovarian cancer［J］.Electrophoresis,2012,33(22):3361-3369.
［25］Zhang T,Wu X,Ke C,et al.Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling［J］.J Proteome Res,2012,12(1):505-512.
［26］Wu ZY,Jia HX,Zhu J,et al.Set of data for ovarian cancer metabolism Boosting algorithm applied research［J］.Chin J Health,2012,29(6):786-789.［武振宇,贾慧珣,朱骥.Boosting 算法对卵巢癌代谢组数据的应用研究［J］.中国卫生统计,2012,29(6):786-789.］
［27］Zhang T,Wu X,Yin M,et al.Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry［J］.Clinica Chimica Acta,2012,413(9):861-868.
［28］Denkert C,Budczies J,Kind T,et al.Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors［J］.Cancer Res,2006,66(22):10795-10804.
［29］Garcia E,Andrews C,Hua J,et al.Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe［J］.J Proteome Res,2011,10(4):1765-1771.
［30］Hao XY.Ovarian cancer patient's urine and HeLa disposed by taxol(TAX) metabonomics analysis［D］.Shandong University,2014.［郝秀玉.卵巢癌患者尿液及紫杉醇处理 HeLa 细胞的代谢组学分析［D］.山东大学,2014.］
［31］Caneba CA,Bellance N,Yang L,et al.Pyruvate uptake is increased in highly invasive ovarian cancer cells under anoikis conditions for anaplerosis,mitochondrial function,and migration［J］.Am J Physiol-Endocrinol Metabolism,2012,303(8):E1036-E1052.
［32］Su Y.The application of metabonomics technology in ovarian cancer research［J］.Diagnosis Treat Practical Magazine,2014,28(12):1152-1154.［苏瑶,李佩玲.代谢组学技术在卵巢肿瘤研究中的应用［J］.中华实用诊断与治疗杂志,2014,28(12):1152-1154.］